{
    "clinical_study": {
        "@rank": "129690", 
        "arm_group": {
            "arm_group_label": "BMS-247550", 
            "arm_group_type": "Experimental", 
            "description": "IV administration of BMS-247550 once every 21 days"
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who\n      have recurrent or metastatic colorectal cancer."
        }, 
        "brief_title": "BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "December 2004", 
            "@type": "Actual"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the objective response rate in patients with locally recurrent or metastatic\n           colorectal cancer treated with BMS-247550.\n\n        -  Determine the toxicity of this drug in these patients.\n\n        -  Determine the duration of response, median and overall survival, and time to\n           progression in patients treated with this drug.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days in the\n      absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 6 weeks.\n\n      PROJECTED ACCRUAL: A total of 21-50 patients will be accrued for this study within 8-10\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed metastatic or locally recurrent\n             adenocarcinoma of the colon or rectum that is not amenable to potentially curative\n             surgical resection\n\n          -  At least 1 unidimensionally measurable lesion\n\n               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan\n\n               -  The following are not considered measurable lesions:\n\n                    -  Lesions seen on colonoscopic examination or barium study\n\n                    -  Bone metastases\n\n                    -  CNS lesions\n\n                    -  Ascites\n\n          -  Failed prior combination therapy comprising fluorouracil, leucovorin calcium, and\n             irinotecan for metastatic disease\n\n          -  No brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-1\n\n        Life expectancy:\n\n          -  At least 3 months\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  ALT/AST no greater than 2.5 times upper limit of normal\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 mg/dL OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Cardiovascular:\n\n          -  No symptomatic congestive heart failure\n\n          -  No unstable angina pectoris\n\n          -  No cardiac arrhythmia\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No grade 2 or greater peripheral neuropathy\n\n          -  No history of allergic hypersensitivity reaction to compounds containing\n             polyoxyethylated castor oil (Cremophor EL) (e.g., paclitaxel or compounds of similar\n             chemical or biological composition to BMS-247550)\n\n          -  No other currently active malignancy (less than 30% risk of relapse and completed\n             prior therapy) except non-melanoma skin cancer or carcinoma in situ of the cervix\n\n          -  No uncontrolled illness\n\n          -  No ongoing or active infection\n\n          -  No psychiatric illness or social situation that would preclude study compliance\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No concurrent immunotherapy\n\n          -  No concurrent colony-stimulating factors during first course of therapy\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  Prior adjuvant chemotherapy allowed\n\n          -  At least 4 weeks since prior cytotoxic chemotherapy and recovered\n\n          -  No more than 1 prior chemotherapy regimen for metastatic disease\n\n          -  No other concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  No concurrent anticancer hormonal therapy\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n          -  No concurrent therapeutic radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior surgery\n\n        Other:\n\n          -  At least 30 days since prior investigational agents\n\n          -  At least 7 days since prior cimetidine\n\n          -  No other concurrent anticancer investigational agents, commercial agents, or\n             therapies\n\n          -  No concurrent unconventional therapy, food, or vitamin supplement containing\n             Hypericum perforatum (St. John's Wort)\n\n          -  No concurrent cimetidine\n\n          -  No concurrent combination antiretroviral therapy for HIV-positive patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00022477", 
            "org_study_id": "11003B", 
            "secondary_id": [
                "UCCRC-11003B", 
                "NCI-3670"
            ]
        }, 
        "intervention": {
            "arm_group_label": "BMS-247550", 
            "intervention_name": "BMS-247550", 
            "intervention_type": "Drug", 
            "other_name": "ixabepilone, Ixempra\u00ae"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "stage IV colon cancer", 
            "stage IV rectal cancer", 
            "recurrent colon cancer", 
            "recurrent rectal cancer", 
            "adenocarcinoma of the colon", 
            "adenocarcinoma of the rectum"
        ], 
        "lastchanged_date": "September 4, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UCCRC-11003B"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "University of Illinois at Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60640"
                    }, 
                    "name": "Louis A. Weiss Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637-1470"
                    }, 
                    "name": "University of Chicago Cancer Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Decatur", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62526"
                    }, 
                    "name": "Decatur Memorial Hospital Cancer Care Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Evanston", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60201"
                    }, 
                    "name": "Evanston Northwestern Health Care"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harvey", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60426"
                    }, 
                    "name": "Ingalls Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "LaGrange", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60525"
                    }, 
                    "name": "LaGrange Memorial Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maywood", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60153"
                    }, 
                    "name": "Loyola University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Park Ridge", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60068"
                    }, 
                    "name": "Lutheran General Cancer Care Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Peoria", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61602"
                    }, 
                    "name": "Oncology/Hematology Associates of Central Illinois, P.C."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62701"
                    }, 
                    "name": "Central Illinois Hematology Oncology Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Wayne", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46885-5099"
                    }, 
                    "name": "Fort Wayne Medical Oncology and Hematology, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Bend", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46601"
                    }, 
                    "name": "Michiana Hematology/Oncology P.C."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Joseph", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49085"
                    }, 
                    "name": "Lakeland Medical Center - St. Joseph"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10461"
                    }, 
                    "name": "Albert Einstein Comprehensive Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study Of Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Advanced Colorectal Carcinoma", 
        "overall_official": {
            "affiliation": "University of Chicago", 
            "last_name": "Hedy L. Kindler, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Response rate of BMS-247550 in colon cancer", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00022477"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Chicago", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2001", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }, 
    "geocoordinates": {
        "Albert Einstein Comprehensive Cancer Center": "40.85 -73.867", 
        "Central Illinois Hematology Oncology Center": "39.782 -89.65", 
        "Decatur Memorial Hospital Cancer Care Institute": "39.84 -88.955", 
        "Evanston Northwestern Health Care": "42.041 -87.69", 
        "Fort Wayne Medical Oncology and Hematology, Inc.": "41.079 -85.139", 
        "Ingalls Memorial Hospital": "41.61 -87.647", 
        "LaGrange Memorial Hospital": "38.965 -89.417", 
        "Lakeland Medical Center - St. Joseph": "42.098 -86.484", 
        "Louis A. Weiss Memorial Hospital": "41.878 -87.63", 
        "Loyola University Medical Center": "41.879 -87.843", 
        "Lutheran General Cancer Care Center": "42.011 -87.841", 
        "Michiana Hematology/Oncology P.C.": "41.683 -86.25", 
        "Oncology/Hematology Associates of Central Illinois, P.C.": "40.694 -89.589", 
        "University of Chicago Cancer Research Center": "41.878 -87.63", 
        "University of Illinois at Chicago": "41.878 -87.63"
    }
}